We report the results of a prospective non-randomized phase II study of Muromonab-CD3 (Orthoclone OKT3 s ), an anti-CD3 monoclonal antibody, with methylprednisolone (MP) and cyclosporine (CSA) for acute GVHD (aGVHD) prophylaxis in 22 hematologic malignancy patients. OKT3 was given at 0.1 mg/kg/day with a maximum dose of 5 mg/day. Initial MP dose was 1000 mg before OKT3, with subsequent doses at 1 mg/kg/ day before each OKT3 infusion with a planned taper beginning at day þ 28. CSA (3 mg/kg/day) was given as a continuous infusion at day À1 and adjusted to maintain serum levels between 250 and 399 ng/ml. Allogeneic BMT donors were HLA-matched siblings (n ¼ 17), single HLAmismatched-related (n ¼ 1) and HLA-matched unrelated (n ¼ 4). All patients achieved neutrophil engraftment at a median 11 days (range, 8-25 days). By intent-to-treat, the cumulative incidence of grade II-IV aGVHD was 33% (95% CI 13-53%) at a median 26 days post-BMT (range, 14-84 days). Chronic GVHD developed in 11/12 evaluable patients. Eight patients (36%) developed OKT3 first dose reactions; no cases of post-transplant lymphoproliferative disorder were observed. OKT3 depleted peripheral CD3 þ cells in vivo as measured by flow cytometry. OKT3 þ MP þ CSA combination is moderately effective aGVHD prophylaxis, however, it is unlikely to be superior to CSA þ MTX.
Introduction

Muromonab-CD3 (Orthoclone OKT3
s , Ortho-Biotech Products, LP, Bridgewater, NJ, USA) is an IgG2a subclass murine monoclonal antibody against CD3 that directly reacts with the T cell. 1 The structure recognized by OKT3 is linked to the T-cell antigen receptor (TcR), specifically the e chain of CD3 receptor, initiating clearance of the TcR from the membrane surface which silences T-cell allo-reactivity by inducing apoptosis. OKT3 has been shown to be effective in both the prevention and treatment of acute rejection of solid organ transplants. 2, 3 OKT3 and related antibodies have been primarily utilized for the treatment of aGVHD in alloBMT. [4] [5] [6] [7] OKT3 in combination with methotrexate (Mtx) and prednisone for aGVHD prophylaxis has been reported to be associated with a similar incidence of aGVHD compared to the combination of antithymocyte globulin (ATG), Mtx and prednisone. 8 However, the management of aGVHD has changed considerably since the publication of the latter study in 1994. In addition, OKT3 has not been integrated into standard aGVHD prophylaxis regimens utilizing cyclosporine (CSA) or tacrolimus (FK-506) with or without Mtx.
We conducted a prospective non-randomized phase II study to determine the efficacy and safety of OKT3 in combination with CSA and methylprednisone (MP) for the prophylaxis of aGVHD. In an effort to reduce the rate of aGVHD, OKT3 was studied at our institution as a means to replace Mtx and possibly decrease toxicity, mucositis and enhance engraftment.
Patients and methods
Patients
Twenty-two patients with hematologic malignancies were enrolled in a prospective non-randomized phase II clinical trial of OKT3 for aGVHD prophylaxis in alloBMT at Roswell Park Cancer Institute (RPCI) between April 1997 and September 1999. Standard eligibility criteria included age 45 and o65, and adequate cardiac, pulmonary, hepatic and renal function and performance status. Patients allergic to mouse proteins, with seizure disorders or those who had undergone a previous alloBMT were excluded. This clinical trial received institutional review board approval, all patients signed informed consent and all data have been de-identified.
Transplantation
Conditioning regimens varied according to donor relation, degree of HLA-match, underlying diagnosis and disease status. Thirteen patients received etoposide (VP-16) 1800 mg/m 2 , cyclophosphamide (Cy) 60 mg/kg, and 1000 cGy total body irradiation (TBI) in five fractions. 9 Five patients were treated with thiotepa (Tt) and 1000 cGy TBI.
10 Busulfan (Bu) 16 mg/kg and Cy 120 mg/m 2 (BuCy) conditioning was used in two patients. 11 Two patients received fludarabine (Flu) 125 mg/m 2 plus melphalan (M) 140 mg/m 2 . 12 All patients received bone marrow as the source of stem cells. All patients received standard BMT supportive care including immunoglobulin (IVIG) and antimicrobial prophylaxis with fluconazole and acyclovir. HLA typing was performed for all related BMT patients at HLA-A, -B and -DR loci by serologic methods; unrelated BMT patients had HLA typing at HLA-DR by molecular methods. All patients except one were HLA-matched (6/6) at these three loci; one patient received a 5/6 HLAmismatched transplant from the patient's child.
Hematopoietic recovery
Successful engraftment of infused stem cells was defined as an absolute neutrophil count (ANC) X500/mm 3 for 3 consecutive days and a platelet count of X20 000/mm 3 after 7 consecutive days of no platelet transfusions. Granulocyte colony-stimulating factor (G-CSF) was administered from the date of stem cell transfusion until neutrophil engraftment was acheived. Patients who survived for 60 days post BMT without neutrophil or platelet recovery were considered engraftment failures. aGVHD prophylaxis and treatment aGVHD prophylaxis consisted of OKT3, MP and CSA with the following schedule: Muromonab-CD3 (Orthoclone s OKT3, Ortho Pharmaceuticals, Raritan, NJ, USA) was given as an intravenous (i.v.) push in o1 min at day þ 7 from stem cell infusion and continued once daily until day þ 21. A chest X-ray was obtained at least 24 h before drug administration and O 2 saturations were monitored. MP was administered for prophylaxis 1 h before the first dose of OKT3 as an i.v. bolus of 1000 mg followed by oral MP 1 mg/kg 30 min after the OKT3 infusion. Thereafter, oral or i.v. MP 1 mg/kg/day was given before each OKT3 infusion for 13 days followed by a taper beginning at day þ 28 with a plan to discontinue MP by day þ 100. Patients were also pre-medicated with diphenhydramine and acetaminophen to counteract the mitogenic cytokine release after OKT3 delivery. The first patient developed systemic toxicity from OKT3 after the administration of 0.1 mg/kg/ day first dose. Thereafter, the dose of OKT3 was reduced to 5.0 mg maximum, which was then employed as the daily dose regardless of body weight. Median weight of the patients was 81.2 kg (range, 26.2-111). All patients received 5 mg/day OKT3 except one pediatric patient who received 2.6 mg/day.
CSA was started as a continuous i.v. infusion at day À1 at a dose of 3 mg/kg/day and adjusted to maintain serum levels between 250 and 399 ng/ml. CSA was switched to oral formulation to maintain the same serum levels until day þ 60, and then tapered until discontinuation by days 90-100 if there was no evidence of aGVHD.
Any incidence of moderate to severe aGVHD (overall grade II-IV) was initially treated with an increased dose of MP at 2-10 mg/kg/day. If toxicities arose from CSA treatment, tacrolimus (FK-506) was substituted. Grade I cutaneous aGVHD was treated with topical corticosteroids only.
Flow cytometry
Peripheral blood leukocytes were isolated from blood samples on days þ 14, þ 21 and þ 28 post-BMT (days þ 7, þ 14 and þ 21 of OKT3 therapy). Multi-parameter flow cytometry was performed in the Laboratory of Flow Cytometry at Roswell Park Cancer Institute, as previously described. 13 Briefly, whole blood was washed in PBS and then stained with mAb cocktails containing CD3 FITC or CD3 APC (clone SK7), CD4 PE (clone SK3), CD8 PerCP (clone SK1) and CD5 FITC (clone 10V) (all from BD BioSciences, San Jose, CA, USA) in the presence of mouse IgG (Invitrogen, Burlingame, CA, USA) to block Fc receptors. The red cells were then lysed with ammonium chloride and the remaining cells washed and fixed in 2% EM grade formaldehyde (Polyscience, Warrington, PA, USA). Cytofluorometric analysis was performed using a FACSCalibur (BD BioSciences, San Jose, CA, USA) flow cytometer equipped with 488 nm argon-ion and 635 nm red diode lasers. Forward scatter, side scatter and four fluorescent parameters were collected. The lymphocyte region was defined by forward and side scatter and the percentage of antibody positive cells falling within this region was calculated (% gated). Data were analyzed using WinList multi-parameter analysis software (Verity Software House, Topsham, ME, USA).
Statistical analysis
Descriptive statistics were used to summarize patient characteristics and outcomes. Survival was defined as the time from day 0 (infusion of stem cells) until death or censored at last follow-up as of 1 October 2005. Overall survival was calculated using the Kaplan-Meier method, with 95% confidence intervals for the point estimates. Cumulative incidence curves estimate the probabilities of time to neutrophil engraftment and aGVHD. Univariate analysis of the flow cytometry data comparing mean cell counts and proportions over time (days þ 14, þ 21 and þ 28) used the ANOVA test.
Criteria were used to assess regimen related toxicities (RRT) in eight organ systems including cardiac, renal, bladder, pulmonary, hepatic, gastrointestinal, mucosal and central nervous system as previously defined. 14 aGVHD up to day 100 was classified according to published criteria. 15 OKT3, MP and CSA for aGVHD prophylaxis M Benekli et al
Results
Patients
Patient characteristics are summarized in Table 1 . Seventeen patients were analyzable for efficacy and 22 patients were analyzable for toxicity of treatment. Three patients were not evaluable for efficacy since their immunosuppression was discontinued due to progression of underlying disease. Two additional patients were not evaluable for efficacy due to acute toxicity with the first dose OKT3 (n ¼ 1) and discontinuation of OKT3 due to multi-organ failure not related to OKT3 treatment (n ¼ 1). All patients, except two, had advanced disease at the time of BMT defined as chronic myeloid leukemia not in first chronic phase and lymphoma or acute leukemia not in first complete remission (CR) Toxicity Twenty-two patients received at least one dose of OKT3 and were evaluable for toxicity. Eight patients (36%) developed first dose reactions after OKT3 administration. Most of the reactions were mild including fever, shortness of breath, chills and generalized myalgias. One patient experienced a severe reaction characterized by angioedema and mild global tremors after a body weight adjusted first dose of 9.94 mg. The second dose was reduced to 5 mg and OKT3 was subsequently discontinued due to severe systemic reactions. None of the patients required intubation or developed post-transplant lymphoproliferative disorder (PTLD). Additionally, 11 patients developed grade I and six patients grade II stomatitis by published criteria.
14 There were no cases of grade III or IV stomatitis. Eight patients developed non-fatal bacteremia before day 100 all of which resolved with antibiotic therapy. Two patients developed three non-fatal yeast infections (oral thrush, stool, upper respiratory tract infection). Seven patients developed CMV viral reactivation, two of whom had a fatal CMV infection. The incidence and severity of these infections was comparable to our contemporaneously treated patients who were not enrolled on this trial (data not shown).
Graft-versus-host disease
Seventeen patients were evaluable for the development of aGVHD, seven of whom developed overall grade II-IV aGVHD at a median onset of 26 days post-BMT (range, 14-84 days). By intent-to-treat, the cumulative incidence of grade II-IV aGVHD was 33% (95% CI 13-53%, Figure 1 ). One patient developed grade II, three patients grade III and three patients grade IV aGVHD (Table 2) . aGVHD Table 1 Characteristics of 22 allogeneic BMT patients treated with OKT3, cyclosporine and methylprednisolone for GVHD prophylaxis 2  0  4  3  2  2  2  Liver  4  2  3  0  4  0  0  G I  0  0  0  1  0  3  2  Overall grade aGVHD  IV  III  IV  II  IV  III  III OKT3, MP and CSA for aGVHD prophylaxis M Benekli et al resolved in all patients except two who died from aGVHD and three who died from disease progression and/or infection with active aGVHD. Of note, two of four patients undergoing unrelated donor BMT and the patient who had a single HLA-antigen mismatched related BMT developed grade II-IV aGVHD. In a subset analysis of HLA-matched siblings, the cumulative incidence of grade II-IV aGVHD was 25% (95% CI, 4-46%). Of the 13 patients surviving 100 days post-BMT, 11 (85%) developed chronic GVHD at a median onset of 160 days post-BMT (range, 105-554 days). Four patients experienced limited chronic GVHD and seven patients experienced extensive chronic GVHD. One patient died of chronic pulmonary GVHD (day þ 691).
Survival
Thirteen of the 22 patients (59%) survived past 100 days. Median overall survival was 9.6 months (95% CI 0-48 months) for all patients. At a median follow-up of 7.6 years (range 6.7-8.2 years) in the survivors, eight patients were alive, seven of whom were also disease free. One patient is alive after receiving a second allogeneic BMT and donor lymphocyte infusions for relapsed AML. Causes of death were RRT from conditioning regimens (veno-occlusive disease n ¼ 2, pulmonary toxicity n ¼ 2), disease progression (n ¼ 3), infection (n ¼ 3), aGVHD (n ¼ 2), chronic GVHD (n ¼ 1) and myocardial infarction (n ¼ 1). Table 3 shows the level of T-cell-specific leukocyte antigens by the conventional scatter gating method. OKT3 can block the detection of CD3 þ cells by interfering with the binding of anti-CD3 antibodies. CD5 is coexpressed on CD3 þ T cells (as well as a small population of circulating B cells), thus CD5 was also used as a measure of T-cell numbers. Median CD3 counts were low during treatment with OKT3 (days þ 14 and þ 21) but increased one week following the last OKT3 dose (day þ 28). The number of circulating CD5 þ cells was also low on day þ 14 and increased on days þ 21 and þ 28. At the day þ 14 and þ 21 time points, the number of CD5 þ cells remained significantly higher than the number of CD3 þ cells at all three time points. As CD5 is an antigen found predominantly on T cells, these data confirm the effectiveness of OKT3 in its ability to bind to the e arm and induce opsonization of the associated TcR complex, rendering the T-cell anergic. Total T-cell counts measured by CD4 þ and CD8 þ cell surface markers were also low as the opsonization of the TcR has previously been shown to induce apoptosis.
Flow cytometry
Discussion
The current standard aGVHD prophylaxis consists of CSA and Mtx combined. 16 In our study, OKT3 was moderately effective in preventing aGVHD when combined with MP and CSA resulting in a 33% cumulative incidence of grade II-IV aGVHD. The efficacy of this novel regimen was comparable to literature data and our previous experience with CSA and Mtx. [16] [17] [18] Our phase II study indicates that OKT3 can safely replace Mtx for aGVHD prophylaxis, but a 14-day course of OKT3 with CSA-MP does not appear to be more efficacious than MTX þ CSA. A different schedule of OKT3 might result in earlier T-cell inactivation and prevention of aGVHD. Different approaches would include starting at an earlier time post-BMT (day þ 1) or the addition of other immunosuppressive agents after OKT3 administration. Furthermore, two of the regimens Table 3 Flow cytometry results for peripheral T-cells collected after seven doses (Day +14 post BMT), 14 doses (Day +21) and 7 days after the last dose of OKT3 (Day +28) for 10 patients with complete data We have since discontinued using these regimens for myeloablative conditioning due to toxicity. OKT3 has been mainly used in the treatment of aGVHD with various results. [4] [5] [6] [7] However, the treatment was associated with a substantial risk of infusion-related side effects, infectious complications and PTLD. In an attempt to prevent aGVHD, pre-treatment of human bone marrow with heterologous anti-T-cell antibodies ex vivo has been safely utilized with successful engraftment of marrow stem cells and OKT3-bound T-cells in bone marrow. 19 Based on these findings, in a clinical trial of aGVHD prophylaxis, Filipovich et al.,
8 compared OKT3, Mtx and prednisone with the ATG, Mtx and prednisone regimen. They reported a similar incidence of aGVHD in both groups with acceptable toxicity.
Wide-spread use of OKT3 in the prevention of aGVHD has not been adopted largely because of considerable toxicities associated with the first dose. [2] [3] [4] Most common symptoms are fever and chills possibly due to the release of inflammatory cytokines such as interleukin (IL)-1, IL-2, interferon gamma and tumor necrosis factor alpha. In our study, pre-OKT3 administration of MP, diphenhydramine and acetaminophen was effective in reducing the severity of these reactions. First dose reactions occurred in 36% of the patients and were generally mild. Only one of our patients developed life-threatening angioedema and subsequent doses of OKT3 were discontinued in this patient. A nonmitogenic anti-CD3 antibody, visilizumab has been used for the treatment of steroid refractory aGVHD. 20 This antibody has shown effectiveness for treating aGVHD, however, use was associated with PTLD requiring the use of rituximab to prevent PTLD. There were no cases of PTLD with more than 6-8 years of follow-up in this study. However, two patients died of CMV infection, which might be related to OKT3 treatment.
We have shown that the administration of OKT3 is effective at reducing the number of peripheral CD3 þ T-cells. It remains to be determined if this decline of T-cells at days þ 7 to þ 21 is the correct time frame for limiting the occurrence of aGVHD. The timing of OKT3 administration may need to coincide with stem cell infusion or engraftment. Alternatively, the number of doses might be increased. These are further questions, which need to be addressed before OKT3 can become a more effective method of aGVHD prophylaxis.
